Immunic Inc (NASDAQ:IMUX) has announced its participation in the Association of European Coeliac Societies (AOECS) 35th General Assembly Conference 2023 taking place November 2 to 5, in which the company will present data from its phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 in patients with celiac disease.
As well, members of its business development, investor relations and public relations teams will attend the BIO-Europe conference in Munich, Germany from November 6 to 8, and participate in partnering activities.